Form 4 for PCVX Vaxcyte, Inc.
Accepted 2024-10-28 00:00:00 ET · period of report 2024-10-25 · accession 0001649094-24-000084 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-10-28 | 2024-10-25 | PCVX | GUGGENHIME ANDREW | Pres AND CFO | M - OptEx | $20.93 | +19.1K | 109.5K | +21% | +$399.9K |
| D | 2024-10-28 | 2024-10-25 | PCVX | GUGGENHIME ANDREW | Pres AND CFO | M - OptEx | $0.00 | -19.1K | 125.9K | -13% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-10-25 | M | A | 19,108 | $20.93 | 109,491 | D | — | — | (F1) Shares are subject to the restrictions on transfer set forth in a Lock-Up Agreement dated September 4, 2024. |
| 2 | Derivative | Stock Option (right to buy) | 2024-10-25 | M | D | 19,108 | $0.00 | 125,892 | D | $20.93 · — to 2031-03-31 | 19,108 Common Stock | (F2) 1/48 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. |